dr. bauml on keynote-055 study for patients with hnscc
Published 8 years ago • 81 plays • Length 1:41Download video MP4
Download video MP3
Similar videos
-
5:00
keynote-055:pembrolizumab in hnscc
-
4:46
preliminary results from keynote-055: pembrolizumab in hnscc
-
1:40
dr. bauml on next steps for immunotherapy in head and neck cancer
-
0:46
dr. bauml on the unmet need in head and neck cancer
-
1:26
dr. bauml on immunotherapy combinations in head and neck cancer
-
0:57
dr. joshua m. bauml on the impact of pembrolizumab in head and neck cancer
-
2:22
dr. bauml discusses immunotherapy agents in head and neck cancer
-
7:03
lba8_pr - keynote-048: phase 3 study of first-line pembrolizumab in r/m hnscc
-
56:36
public lecture: immunotherapy & cancer - the latest research
-
11:13
stem cell therapy - dr. siebenhüner | ask the doctor
-
7:13
stage 3 lung cancer: symptoms, treatment. life expectancy | episode 17
-
0:40
dr. joshua m. bauml on pembrolizumab versus chemo in head and neck cancers
-
1:03
dr. bauml discusses immunotherapy in head and neck cancer
-
1:39
dr. bauml discusses biomarkers in head and neck cancer
-
3:47
pembrolizumab as treatment for oligometastatic nsclc
-
3:55
checkpoint inhibitors for recurrent hnscc
-
1:36
dr. seiwert on prognosis for patients with head and neck cancer
-
7:38
pseudoprogression on immunotherapy in hnscc
-
4:03
keynote-040: groundbreaking results for pembrolizumab in head and neck cancer
-
8:28
outcomes for patients with locally advanced head and neck cancer receiving neoadjuvant pembrolizumab
-
46:17
organization of cell type v2
-
3:23
timing cancer treatment